Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

740results about "Disrupted materials" patented technology

Ultrasound therapy for selective cell ablation

The invention provides a method of sensitising target cells to ultrasound energy using a stimulus such as an electric field. This "electrosensitisation" enables target cells to be disrupted by ultrasound at frequencies and energies of ultrasound which do not cause disruption of non-sensitised (i.e., non-target) cells. As a consequence, the method increases the selectivity of ultrasound therapy, providing a way to ablate undesired cells, such as diseased cells (e.g., tumor cells) while minimising harm to neighboring cells. In another aspect, however, ultrasound can be used to sensitise cells while the electrical field is used to disrupt cells. The invention also provides an apparatus for performing the method and assays for identifying gene products and other molecules involved in apoptosis.
Owner:GENDEL

Device II

Applicants describe a cell ablation apparatus comprising: electric field signal generating circuitry for generating an electric field signal; an electric field delivery component connected to receive the electric field signal and operable to deliver an electric field to a treatment site; ultrasound signal generating circuitry for generating an ultrasound signal; an ultrasound delivery component connected to receive the ultrasound signal and operable to deliver ultrasound to the treatment site; and a controller operable to control the electric field signal generating circuitry and the ultrasound signal generating circuitry in order to ablate a cell at the treatment site. Various electrode configurations suitable for use in such an apparatus and independently are described.
Owner:GENDEL

Method for treating subcutaneous tissues

An apparatus and method for treating subcutaneous tissues using acoustic waves in the range of low acoustic pressure ultrasound waves is disclosed. The method includes injections of enhancing agents, wherein disruption of subcutaneous tissues and subcutaneous cavitational bioeffects are produced by ultrasound waves having a power that will not produce tissue cavitation in the absence of the enhancing agents. The apparatus and method of use is useful for treatment of subcutaneous abnormalities including cellulite, lipomas, and tumors.
Owner:ULTHERA INC

Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders

A method for delivering molecules to a central nervous system (CNS) of a subject includes supplying the molecules to a blood circulation of the CNS; supplying, to a body of the subject, a carrier system that encapsulates a nitric oxide (NO) facilitator; and applying energy to the carrier system at an energy level sufficient to cause the carrier system to release the NO facilitator in a blood circulation of the subject in a vicinity of a blood-brain barrier (BBB) of the subject and thereby increase passage of the molecules from the blood circulation of the CNS, through the BBB, and into the CNS of the subject.
Owner:BRAINSGATE LTD

Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same

A booster comprising a plenty of microbubbles of a gas in a liquid, e.g. about 4x107 cells / ml of microbubbles of a gas having a diameter of 0.1 to 100 mu m in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth above and a medicament, which are useful for the therapy of various diseases together with exposure of ultrasonic, where the therapeutic effects of the medicament is enhanced by the application of ultrasound in the presence of the booster.
Owner:EKOS CORP

Ultrasound Therapy Resulting in Bone Marrow Rejuvenation

A method and system for treating a patient to repair damaged tissue which includes exposing a selected area of bone marrow of a patient to ultrasound waves or ultra shock waves so that cells comprising stem cells, progenitor cells or macrophages are generated in the area of the bone marrow of the patient due to the ultrasound, converting the cells from the bone marrow of the patient and reducing the damaged tissue in the bone marrow of the patient by repairing the damaged tissue.
Owner:JOHNSON LANNY L

Ultrasound therapy for selective cell ablation

The invention provides a method of sensitizing target cells to ultrasound energy using a stimulus such as an electric field. This "electrosensitisation" enables target cells to be disrupted by ultrasound at frequencies and energies of ultrasound which do not cause disruption of non-sensitized (i.e., non-target) cells. As a consequence, the method increases the selectivity of ultrasound therapy, providing a way to ablate undesired cells, such as diseased cells (e.g., tumor cells) while minimizing harm to neighboring cells. In another aspect, however, ultrasound can be used to sensitize cells while the electrical field is used to disrupt cells. The invention also provides an apparatus for performing the method and assays for identifying gene products and other molecules involved in apoptosis.
Owner:GENDEL

Method and articles for remote magnetically induced treatment of cancer and other diseases, and method for operating such article

This invention describes unique treatment methods and innovative articles that can be placed in a human or animal body to enable controlled destruction of diseased tissue. The methods include destruction of diseased cells and tissues by magnetically controlled motion and an externally controllable drug delivery process with a capability to start and stop the drug delivery at any time, for any duration. This invention provides two approaches to diseased cell destruction, (1) magneto-mechanical disturbance of cell structure (e.g. cancer cells) for cell lysis and (2) magnetically activated drug release at local regions (e.g. tumors) from a magnetic-particle-containing drug reservoir. The invention also provides combinations of both the above treatments for dual therapy. It further combines one or both of the treatments with magnetic hyperthermia for multifunctional cell destruction therapy. The approaches can be combined with magnetic MRI for monitoring the accuracy of placement as well as for following up the cancer destruction progress and appropriate reprogramming of the magneto-mechanical therapy and remote-controlled drug release.
Owner:RGT UNIV OF CALIFORNIA

Composition comprising gas-filled microcapsules for ultrasound mediated delivery

Composition comprising gas filled microcapsules and a bioactive agent, useful for an ultrasound-mediated delivery of said bioactive agent. The microcapsules comprise a relatively stiff shell of polymeric or lipid material and have in particular a resistance to a mechanical index of at least 0.15, while the bioactive agent is substantially unbound to the shell of the microcapsules. The composition of the invention is particularly suitable for effectively delivering a genetic material into a cell, upon exposure of the composition to a level of acoustic pressure capable of destroying a portion of the microcapsules and releasing the gas contained therein.
Owner:BRACCO RES USA

Ultrasonic concentration of carrier particles

Methods, compositions, and apparatus for localized delivery of compounds are provided. In certain embodiments, acoustic streaming force is used to direct carrier particles to a target site, mediate particle internalization, and release associate compounds. Ultrasound radiation is preferred as the source for the acoustic streaming force. Also encompassed are embodiments in which targeting and membrane permeability enhancement are combined with imaging of the treatment site.
Owner:RGT UNIV OF CALIFORNIA +1

System for treating subcutaneous tissues

An apparatus and method for treating subcutaneous tissues using acoustic waves in the range of low acoustic pressure ultrasound waves is disclosed. The method includes injections of enhancing agents, wherein disruption of subcutaneous tissues and subcutaneous cavitational bioeffects are produced by ultrasound waves having a power that will not produce tissue cavitation in the absence of the enhancing agents. The apparatus and method of use is useful for treatment of subcutaneous abnormalities including cellulite, lipomas, and tumors.
Owner:ULTHERA INC

Solid hydrogel coupling for ultrasound imaging and therapy

The present invention employs hydrogels as acoustic couplings for clinical applications of ultrasound imaging and therapy, but is particularly applicable to high intensity focused ultrasound (HIFU) based therapy. While other materials can be used, it has been determined that polyacrylamide is sufficiently robust and transmissive to withstand the high temperatures encountered in HIFU therapy. One embodiment of a hydrogel coupling is configured in shape and size (length) to ensure that a focal region of an ultrasound transducer is disposed proximate the target area when the distal tip of the transducer is in contact with tissue. These couplings can be shaped to correspond to the beam focus characteristics of specific transducers. Water can be applied to hydrate the tip of the hydrogel coupling during use, and medication absorbed into the hydrogel material can be applied to the tissue in contact with the distal surface of the hydrogel.
Owner:UNIV OF WASHINGTON

Apparatus for treating subcutaneous tissues

An apparatus and method for treating subcutaneous tissues using acoustic waves in the range of low acoustic pressure ultrasound waves is disclosed. The method includes injections of enhancing agents, wherein disruption of subcutaneous tissues and subcutaneous cavitational bioeffects are produced by ultrasound waves having a power that will not produce tissue cavitation in the absence of the enhancing agents. The apparatus and method of use is useful for treatment of subcutaneous abnormalities including cellulite, lipomas, and tumors.
Owner:ULTHERA INC

Ultrasound imaging and treatment

Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly usefull for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.Gas, gaseous precursors and perfluorocarbons are presented as novel potentiators for ultrasonic hyper-thermia. The gas, gaseous precursors and perfluorocarbons which may be administered into the vasculature, interstitially or into any body cavity are designed to accumulate in cancerous and diseased tissues. When therapeutic ultrasonic energy is applied to the diseased region heating is increased because of the greater effectiveness of sound energy absorption caused by these agents.
Owner:IMARX THERAPEUTICS

Implantable products comprising nanoparticles

The present disclosure relates to nanoparticle-containing implantable and preferably biodegradable medical products and their use for the thermotherapeutic after-treatment after surgical removal of tumors and cancerous ulcers.
Owner:MAGFORCE AG

Gene or drug delivery system

The present invention includes compositions and methods for delivering one or more active agents in vivo by contacting a target organ or tissue with a microbubble encapsulated active agent comprising a neutrally charged lipid microbubble loaded with cationic liposomes comprising one or more active agents and selectively releasing the active agents at the target by exposing the microbubble at the target with ultrasound, wherein the active agents remain protected in the microbubble until selectively release at the target.
Owner:BAYLOR RES INST +1

NIR-sensitive nanoparticle

It is provided a Near Infrared Sensitive (NIR-sensitive) nanoparticle complex comprising a NIR-sensitive nanoparticle and surfactant(s) adsorbed on the nanoparticle, wherein the surfactant is at least one surfactant selected from: wherein X=1-9; Y=0-9; n=0-9; Z=1-9; W=0-9; m=0-9; each of R1, R2, R3 and R4, if present, is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 aryl, HS, COOH, NH2 or OH; R5 is COOH, NH2 or OH; with the proviso that n+m is <10; (b) an amino acid having the structure in (a), wherein X=1; Y=2; Z=1; W=1; R1, R2 and R4 are not present; R3 is NH2; and R5 is COOH; or (c) a peptide, wherein the peptide comprise at least one amino acid (b). Further, it is provided a NIR-sensitive nanoparticle complex(es) having biomolecule(s), for example drug(s), loaded on the surfactant(s).
Owner:NAT UNIV OF SINGAPORE +1

Lipid bilayer carrier for drugs or imaging agents

Disclosed are carriers for drugs and / or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long / short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.
Owner:KONINKLIJKE PHILIPS ELECTRONICS NV

Booster for therapy of disease with ultrasound and pharmaceutical liquid composition containing the same

A booster comprising a plurality of microbubbles of a gas in a liquid, e.g. about 4x107 cells / ml of microbubbles of a gas having a diameter of 0.1. to 100 mum in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth above and a medicament, which are useful for the therapy of various diseases together with exposure of ultrasonic, where the therapeutic effects of the medicament is enhanced by the application of ultrasound in the presence of the booster.
Owner:EKOS CORP

Method and apparatus for delivery of agents across the blood brain barrier

We describe a method for opening the blood-brain barrier (BBB) using ultrasound and preformed microbubbles. With this method, diagnostic or therapeutic agents may be administered to the brain. This method can open a focal region of the BBB and administer agents in a targeted fashion or the method can open large regions (or the entirety) of the brain for more global administration of agents. In one embodiment, the method can be used to administer contrast agents (e.g., agents that increase or decrease the magnetic resonance imaging signal) to the brain and thereby improve the quality or information content of imaging data. In another embodiment, a standard clinical diagnostic ultrasound scanner can be used to open specific regions of the BBB and administer diagnostic or therapeutic agents. Importantly, this invention can open the BBB in a non-destructive / non-invasive fashion, allowing the subject to be awake and suffer no detectable side effects.
Owner:DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products